Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Diamyd submits application to initiate phase III studies of Diamyd in Sweden

Jan. 22, 2008

Genaera initiates phase I trial of trodusquemine in overweight and obese diabetic patients

Jan. 22, 2008

FDA approves Welchol for glucose reduction in adults with type 2 diabetes

Jan. 21, 2008

Karo Bio reports positive results from phase IIb study of eprotirome

Jan. 21, 2008

New PPAR agonists described in recent patent

Jan. 18, 2008

Novartis Pharma and Mitsubishi Tanabe revise agreement for Lochol for hypercholesteremia

Jan. 17, 2008

Taranabant induces weight loss in obese subjects

Jan. 17, 2008

Head to head study comparing rosuvastatin and atorvastatin commences

Jan. 16, 2008

Glenmark's lead diabetes candidate named melogliptin

Jan. 16, 2008

Pfizer submits NDA for Fablyn in osteoporosis

Jan. 16, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...